AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)— COCATS 4 TASK FORCE 2: TRAINING IN PREVENTIVE CARDIOVASCULAR MEDICINE

Committee Member	Employment Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Sidney C. Smith, Jr. (Chair)	University of North Carolina, Heart and Vascular Center—Professor of Medicine	None	None	None	None	None	None
Vera Bittner	University of Alabama at Birmingham—Medical Director, Coronary Care Unit; Professor of Medicine; Section Head, Preventive Cardiology; and Medical Director, Cardiac Rehabilitation	 Amarin Amgen Eli Lilly LipoScience Novartis Pfizer 	None	None	 Amgen AstraZeneca* Bayer† Eli Lilly* GlaxoSmithKline† Hoffman-La Roche† Janssen Pharmaceuticals National Institutes of Health/Abbott (joint effort)† National Institutes of Health/Yale Pfizer Sanofi-aventis* Schering Plough* University of Oxford* 	 ABCL* AHA* ASPC* FDA Foundation of the National Lipid Association* Hoffman-La Roche† National Lipid Association NPRCR* UNC, Chapel Hill/Columbia University, NYC – NIH 	None
J. Michael Gaziano	Brigham and Women's Hospital, Cardiology Division—Chief, Division of Aging	Bayer†NaturemadePfizerSantauru	None	None	None	None	• Defendant, VTE risk and birth control pills, 2011
John C. Giacomini	Stanford University Medical Center, Division of Cardiovascular Medicine— Professor and Associate Chief; Fellowship Director; VA Palo Alto Health Care System—Chief, Cardiology Section	None	None	None	None	None	None

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional/ Organizational or Other Financial Benefit	Expert Witness
Quinn R. Pack	Henry Ford Hospital— Cardiologist	None	None	None	Janssen Pharmaceuticals*	Janssen Pharmaceuticals*	None
Donna M. Polk	Brigham and Women's Hospital—Director, Cardiovascular Fellowship Program	None	None	None	Hoffman-La Roche†	GlaxoSmithKline†Hoffman-La Roche†Merck†	None
Neil J. Stone	Northwestern Medicine; Bonow Professor of Medicine; Preventive Cardiology	Academy of Nutrition and Dietetics	None	None	None	None	None
Stanley Wang	Austin Heart—Cardiologist and Sleep Specialist, Medical Director of Heart Hospital of Austin Sleep Disorders Center	None	None	None	• Amorcyte*	 AHA* Heart Hospital of Austin* Texas Medical Board* 	None

This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of \geq 5% of the voting stock or share of the business entity, or ownership of \geq \$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

ABCL = American Board of Clinical Lipidology; AHA = American Heart Association; ASPC = American Society for Preventative Cardiology; FDA = Federal Drug Administration; NPRCR = National Program to Reduce Cardiovascular Risk; UNC = University of North Carolina; VTE = venous thromboembolism.

^{*}No financial benefit.

[†]Significant relationship.